NCT01464008View on ClinicalTrials.gov

The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C

CompletedOBSERVATIONAL
Enrollment

297

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

May 31, 2011

Study Completion Date

September 30, 2011

Conditions
Chronic Hepatitis C
Interventions
DRUG

Pegylated interferon alfa-2a and ribavirin

all patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland) 135 or 180 µg by subcutaneous injection once weekly, and received twice daily oral ribavirin at a target total daily dose of 13 mg/kg/day. .

Trial Locations (1)

100015

Beijing Ditan hospital,Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Ditan Hospital

OTHER

NCT01464008 - The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C | Biotech Hunter | Biotech Hunter